Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

Next Previous
Trial Profile

An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CASTING
  • Sponsors Roche

    • Most Recent Events

    • 27 Apr 2023 Results of two studies (CASTING-LIBERTO) assessing changes over 4 years in patient-reported outcomes (PROs) in people with relapsing-remitting multiple sclerosis (PwRRMS) who were switched to ocrelizumab after suboptimal response to disease-modifying therapies, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 28 Jun 2022 Results of an analysis assessed the Symbol Digit Modalities Test, measures cognitive processing speed, and the Work Productivity Activity Impairment at 96-week presented at the 8th Congress of the European Academy of Neurology
    • 26 Apr 2022 Interim Results from LIBERTO and 3-Year Data From CASTING ; assessing the efficacy and safety of ocrelizumab, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top